TABLE 1.
Anti-HBV nucleoside analogs against viral replication in the HBV producing cell lines
| Compound | IC50a (μM) for:
|
||
|---|---|---|---|
| HepG2-WT10 | HepG2-SM1 | HepG2-DM2 | |
| l(−)SddC | 0.005 ± 0.001 | 0.035 ± 0.004 | 8 ± 1.6 |
| PCV | 10 ± 0.9 | >200 | >200 |
| l(−)Fd4C | 0.0009 ± 0.0001 | 0.0027 ± 0.0003 | 0.21 ± 0.03 |
| l-FMAU | 0.02 ± 0.002 | 0.08 ± 0.01 | 50 ± 4.5 |
| PMEA | 0.028 ± 0.002 | 0.031 ± 0.003* | 0.07 ± 0.01 |
| QYL685 | 0.16 ± 0.02 | 0.16 ± 0.02* | 0.8 ± 0.1 |
a
Values are means ± standard deviations generated from the analysis of concentration dependence curves, which were plotted using results from triplicate independent experiments. IC50, 50% inhibitory concentration. ∗, P > 0.05 for IC50 of PMEA or QYL685 against HBV replication in HepG2-WT10 cells versus that in HepG2-SM1 cells. P values are <0.01 for all the other comparisons of IC50 of a compound against HBV replication in HepG2-WT10 cells versus that of the same compound in HepG2-SM1 or HepG2-DM2 cells.